SGB-9768

SGB-9768 is an investigational small interfering RNA (siRNA) drug developed by SanegeneBio for the treatment of complement-mediated kidney diseases, including IgA nephropathy (IgAN), C3 glomerulopathy (C3G), and immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN)[2][6][1]. It is a GalNAc-conjugated siRNA designed to specifically target and silence the mRNA of complement component 3 (C3), a central protein in the complement cascade, thereby reducing its synthesis in the liver through RNA interference[1][2][6]. By inhibiting C3 production, SGB-9768 aims to suppress overactivation of the complement pathway implicated in various renal diseases. The drug leverages SanegeneBio’s proprietary GalNAc delivery platform for targeted hepatic uptake, enabling infrequent dosing intervals (every 3 or 6 months) with sustained efficacy and favorable safety profile demonstrated in preclinical studies[1][2][6]. As of early 2025, SGB-9768 has completed Phase I trials in healthy volunteers and entered Phase II clinical development for kidney disease indications[5][3].